Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oxaliplatin hypersensitivity: case report and successful repeat desensitization.

David A Edmondson1, B J Gruling, Angela M Urmanski

  • 1Allergy and Immunology Ear, Nose, and Throat Associates of North Central Wisconsin, Wausau, WI 54401, USA. dedmondson@westernu.edu

American Journal of Therapeutics
|February 17, 2007
PubMed
Summary

This study shows a successful oxaliplatin desensitization protocol without premedication for a patient with hypersensitivity reactions. This approach may help patients avoid cumulative exposure to pretreatment medications during chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiation-induced remodeling of the T cell landscape in head and neck cancer.

Cancer immunology, immunotherapy : CII·2026
Same author

Radiation-Induced Loss of Tumor-Reactive T Cells Calls for More Rationally Designed Radioimmunotherapy Approaches.

International journal of radiation oncology, biology, physics·2025
Same author

Decreased Severity of Oral Immunotherapy Induced Gastrointestinal Eosinophilic Reactions Following Revisions in Milk-Treatment Protocol.

Allergy·2025
Same author

Effects of Oral Immunotherapy on the Growth Trajectories of Food-Allergic Children.

The journal of allergy and clinical immunology. In practice·2025
Same author

Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Journal for immunotherapy of cancer·2025
Same author

Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology RTOG 9911.

International journal of radiation oncology, biology, physics·2025

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Medicine

Background:

  • Oxaliplatin, a platinum-based chemotherapy agent, is used for colorectal carcinoma.
  • Hypersensitivity reactions to oxaliplatin occur in 12-16% of patients.
  • Previous desensitization protocols often involve premedication with steroids or antihistamines.

Observation:

  • A 43-year-old male with metastatic rectal adenocarcinoma developed urticaria after oxaliplatin infusion.
  • Skin prick and intracutaneous testing for oxaliplatin hypersensitivity were negative.
  • A novel desensitization protocol without premedication was initiated.

Findings:

  • The patient received oxaliplatin desensitization starting at a 1:10,000 dose, gradually increasing to the therapeutic dose.
  • The protocol was successfully repeated for 11 cycles without hypersensitivity reactions.

Related Experiment Videos

  • Tumor remission was observed following treatment.

    • Implications:

    • Oxaliplatin desensitization without premedication is a viable option for patients with hypersensitivity.
    • This approach can reduce the need for additional pretreatment medications.
    • Successful desensitization allows for continued chemotherapy in hypersensitive patients.